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Abstract Whereas human parvovirus B19 commonly infects
children and causes erythema infectiosum, it causes more severe
diseases when it infects adults. In order to examine whether
different clinical outcomes of B19 infection can be ascribed to the
viral genetic heterogeneity, we have determined the nucleotide
sequence of highly immunogenic portions of the B19 genome
obtained from six patients with various clinical manifestations in
a single outbreak. Our observations demonstrated that although
the B19 sequences showed a significant heterogeneity, it was not
correlated with the clinical manifestation. It was thus suggested
that the host immune response to B19 infection may be a major
determinant of clinical presentations associated with acute B19
infection.
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1. Introduction
Human parvovirus B19 is a member of the genus Erythro-
virus of the family Parvoviridae and commonly infects chil-
dren, causing erythema infectiosum (EI) [1,2]. B19 infection
also causes more severe diseases such as acute and persistent
arthritis in young women [3], aplastic crisis [4,5] or hydrops
fetalis [6]. In addition, there are small percentages of adult
patients who develop symptoms mimicking systemic lupus
erythematosus (SLE) (for a review see [7]).
The genome of B19 encodes a non-structural protein NS1
and two structural proteins, the minor structural protein VP1
and the major structural protein VP2, that comprise the B19
capsid. The non-structural protein NS1 is known as a trans-
activator protein for the viral DNA replication [8]. An other
biochemical function of NS1 is in cytotoxicity which is closely
related to apoptosis, although the mechanism underlying the
NS1-induced cell death is not well known [9,24]. Two struc-
tural proteins are encoded in the same reading frame and the
entire nucleotide sequence of VP2 (554 amino acids (aa)) lies
within the VP1 (781 aa) encoding region. These B19 structural
proteins are known to determine the virus tropism and elicit
neutralizing antibody responses [10^13]. Among the di¡erent
regions of viral capsid proteins, the unique region of VP1
(vV), located external to the capsid, is known to be immuno-
genic as well as most variable [12^15]. In addition, the junc-
tion region between VP1 and VP2 (VP1/VP2) is also known to
be immunogenic despite its predicated location interior to the
capsid [16].
The basis for the complex pattern of B19-associated dis-
eases is yet to be determined. Two possibilities are enter-
tained: ¢rstly, di¡erences in the B19 genome may result in
di¡erent outcomes of infection and secondly, the infected in-
dividuals may have a genetic or acquired predisposition. In
order to evaluate the contribution of viral heterogeneity to the
B19-associated diseases, we have determined the nucleotide
sequences of the vV and VP1/VP2 regions, which are known
to be immunogenic, in the patients infected with parvovirus
B19.
2. Materials and methods
2.1. Patients
During the limited period between June 16 and July 25, 1997, we
experienced an outbreak of parvovirus B19 infection involving 13
cases in a pediatric surgery ward at the Nagoya City University Hos-
pital. These cases included four pediatric patients, two patient’s moth-
ers and seven nurses of the same ward. We did not experience such an
outbreak in other wards during this period. Diagnosis of parvovirus
B19 was made based on clinical and laboratory ¢ndings including
typical skin rash, polyarthritis in the adult cases, local epidemics of
EI at the time of this outbreak and detection of B19 virus-speci¢c IgM
and IgG antibodies using enzyme-linked immunosorbent assay. We
excluded other virus infections such as infectious mononucleosis (Ep-
stein-Barr virus) or exanthem subitum (human herpesvirus type 6)
based on clinical presentations and serological tests.
2.2. DNA samples
DNA was obtained from sera of these patients using QIAamp
Blood kit (QIAGEN, Hilden, Germany). The designation of each
serum used is given in Table 1.
2.3. PCR ampli¢cation and cloning
Oligonucleotide primers used for PCR ampli¢cation were vV F:
GGTTGATTATGTGTGGG and vV R: ACTGAAGTCATGCT-
TGG for the VP1 unique region (vV) [13], VP1/VP2 F: TGAC-
AGTGCTGCAAGGATTC and VP1/VP2 R: TGCTGTCAGTAA-
CCTGTACC for the junction region (VP1/VP2). B19 DNA
sequences were ampli¢ed by using the Expand High Fidelity PCR
System (Boehringer Mannheim, Germany) to generate a 692 bp prod-
uct containing the vV region (using vV F and vV R primers) and a
658 bp product containing the VP1/VP2 junction region (using VP1/
VP2 F and VP1/VP2 R primers). These DNA fragments were then
cloned into a vector pCR-Blunt (Invitrogen, Carlsbad, CA, USA) for
further sequencing analysis.
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2.4. DNA sequencing
At least 2^7 independent bacterial colonies were isolated and plas-
mids were puri¢ed. The sequencing reactions were performed using
the ABI PRISM dye terminator cycle sequencing kit (Perkin Elmer,
Foster, CA, USA) and an ABI PRISM 310 Genetic Analyzer (Perkin
Elmer, Foster, CA, USA). The universal M13 primers as well as both
forward and reverse PCR primers were used to con¢rm the sequences
of vV and VP1/VP2 regions. The nucleotide sequence data in this
paper were submitted to the DDBJ, EMBL and GenBank databases
and were assigned the accession numbers AB015949^AB015960 and
AB018642^AB018643.
2.5. Data analyses
Sequence comparison and phylogenetic analysis were performed
using Genetyx-Mac Version 9.0 (Software Development, Tokyo, Ja-
pan). The dendrogram was generated using the uncorrected distances
and grow tree evolutionary analysis programs by the neighbor-joining
method [17].
3. Results
3.1. Description of the outbreak of parvovirus B19 infection in
a pediatric surgery ward
On June 16, 1997, a 9 month old patient (A) developed
generalized erythema on the face, trunk and extremities asso-
ciated with low-grade fever. Within one week, similar skin
erythema associated with various other clinical manifestations
developed in four young nurses (B, C, D and E) of the same
ward. Until July 25, a total of 13 individuals including pedia-
tric patients, their mothers and nurses showed similar symp-
toms (Fig. 1). On August 4, the Nosocomial Infection Com-
mittee of the University Hospital was held to discuss the
etiology of this epidemic. Diagnosis of parvovirus B19 infec-
tion was made based on clinical symptoms and laboratory
tests. No further transmission was observed due to universal
precaution to limit viral infection although the high incidence
of B19 infection subsequently occurred in local communities.
We could not identify the route of B19 infection to the ¢rst
patient A since his family developed B19 disease after he dis-
charged from the hospital. However, it was likely that 13
patients were involved in the same outbreak of B19 infection,
yet clinical manifestations varied among them.
As demonstrated in Fig. 1, nurse C was initially suspected
to have SLE because of her malar rash, arthritis, positive anti-
nuclear antibodies, hypocomplementemia and past history of
photosensitivity. Weight loss and lymphadenopathy were also
noted. All of her symptoms disappeared spontaneously by the
end of July and anti-nuclear antibodies became negative by
December 18, 1997. In one case, both mother F and her
daughter J were involved. Mother F developed EI on June
25 and was positive for both IgG and IgM anti-B19 antibod-
ies. Her 3 year old daughter J developed EI on July 7 and was
positive for IgG but negative for IgM anti-B19 antibodies (in
both cases, the blood sample was drawn on July 16). These six
patients (three nurses (B, C and K), mother F and her daugh-
ter J and patient I) were chosen for this study, because they
presented distinct clinical pictures and their samples were
available for the viral DNA sequence analysis.
3.2. Comparison of the nucleotide and amino acid sequences
among parvovirus B19 isolates
A 692 bp DNA fragment corresponding to the VP1 unique
region (vV) was ampli¢ed using vV F and vV R primers from
six patients (Table 1). Similarly, a 658 bp DNA fragment
corresponding to the junction region (VP1/VP2) of VP1 and
VP2 genes was obtained using VP1/VP2 F and VP1/VP2 R
primers. Fig. 2 depicted the locations of the ampli¢ed viral
DNA segments analyzed in this study. No ampli¢cation was
detected in healthy controls.
The nucleotide sequences of the vV and the VP1/VP2 re-
gions were thus determined. At least two independent colonies
were selected for sequencing in each case. Most of these viral
sequences were identical. However, since the sequences of
both mother F and her daughter J were di¡ered between
two colonies, we sequenced ¢ve additional colonies from
both mother F and daughter J. Whereas B19 sequences of
the additional colonies ampli¢ed from daughter J were iden-
tical, we detected three distinct vV genotypes in mother F
(designated as F-1, F-2 and F-3) (see Table 1 for nomencla-
ture and accession numbers).
Fig. 1. Clinical courses of all 13 patients in this study. The gray,
solid and shaded boxes indicate erythema infectiosum, polyarthritis
and positive anti-nuclear antibodies, respectively. Among 13 pa-
tients, six patients (italicized bold letters) were selected for this study
as described in the text.
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3.3. Genetic heterogeneity at the vV region
Table 2 demonstrates the positions of amino acid substitu-
tions within the vV region among the isolates obtained in this
study as compared from the standard B19-Au sequence [18].
In a comparison of these eight isolates with the standard B19-
Au sequence, the variability of the vV region ranged from
0.29 to 0.87% at the DNA and 0.43^2.17% at the protein
level. Comparing with another standard B19 sequence,
U38509 [19] obtained from a Japanese patient in 1983, the
variability was 0.87^1.45% at the DNA and 1.74^2.17% at
the protein level. All nucleotide di¡erences among the isolates,
as well as in comparison with the standard sequences, were
base substitutions, no insertions or deletions were identi¢ed. It
was noted that the amino acid sequences of parvovirus B19
isolates obtained from nurse C and nurse K were identical.
Among the three distinct strains of mother F, F-1 and F-3
di¡ered at the DNA level (data not shown) but were identical
to each other at the protein level, whereas F-2 appeared to
have a di¡erent amino acid sequence from F-1 and F-3 (Table
2). The amino acid sequences of B19 isolates from mother F
indicated that she was likely to be infected by at least two
di¡erent B19 strains or they might have been arisen during the
replication. It is unlikely that B19 virus of her daughter J was
transmitted from mother F. All eight isolates showed that the
amino acid at position 12 changed from aspartic acid (of B19-
Au), an acidic polar amino acid, to asparagine, an uncharged
polar amino acid. In the N-terminal region, there were nota-
ble substitutions between lysine, a basic amino acid, to gluta-
mic acid, an acidic amino acid.
3.4. Genetic heterogeneity at the VP1/VP2 region
The junction region (VP1/VP2) between the encoding se-
quences of the two structural proteins (VP1 and VP2) was
similarly analyzed. The VP1/VP2 region was almost identical,
except one nucleotide change, among the isolates obtained in
this study. In comparison with the standard B19-Au, nucleo-
tide substitutions were evenly distributed throughout this re-
gion and the variabilities were ranged from 0.61 to 0.76% at
the DNA and 0.46^0.91% at the protein level. Sequence iden-
tity was noted for nurse B, mother F, her daughter J and
patient I. Similarly, the sequences from nurse C and nurse
K were identical. All six isolates showed that the amino
acid at position 95 changed from serine (of B19-Au), an un-
charged polar amino acid, to proline, a non-polar amino acid
(Table 3).
3.5. Phylogenetic analysis of the parvovirus B19 isolates
To assess the genetic relationships among the B19 isolates,
dendrograms were constructed using the neighbor-joining
method [17] based on calculation of the similarity score ob-
tained by pair-wise comparisons of the nine B19 vV and seven
VP1/VP2 nucleotide sequences including the standard B19-Au
sequence. Isolates from individuals obtained in this study ex-
hibited a high degree of genetic similarity among others (Fig.
3). Although the vV showed genetic heterogeneity, especially
in the N-terminal region, the VP1/VP2 showed only subtle
changes.
3.6. Comparison of viral genotypes and clinical manifestations
Among the cases studied, there was no signi¢cant correla-
Fig. 2. Schematic representation of parvovirus B19 open reading frames. Numbers represent nucleotide numbers on the parvovirus B19 genome.
The upper part indicates the locations of NS1, VP1 and VP2 proteins. In the lower part, the regions ampli¢ed by PCR are shown. vV, the
VP1 unique region; VP1/VP2, the junction region of VP1 and VP2.
Table 1
Patients pro¢les
Case Age Sex Date of onset Clinical presentation Serological tests Accession number
IgM IgG vVa VP1/VP2b
Nurse B 22 year Fc 6/19/1997 EId, ARe + + AB015955 AB015950
Nurse C 28 year F 6/23/1997 EI, AR, SLE-like + + AB015956 AB015951
Mother F 30 year F 6/25/1997 EI + + (F-1)f AB015957 AB015952
(F-2)f AB018642
(F-3)f AB018643
Patient I 3 year F 7/7/1997 EI + + AB015954 AB015949
Patient J 3 year F 7/7/1997 EI 3 + AB015960 AB015959
Nurse K 24 year F 7/14/1997 AR + 3 AB015958 AB015953
avV, the unique region of VP1.
bVP1/VP2, the junction region between VP1 and VP2.
cF, female.
dEI, erythema infectiosum.
eAR, arthritis.
f F-1, F-2, F-3, indicated in the text.
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tion between the viral genotypes and the clinical presentations
(Table 1). For example, nurses K and C, whose viral sequen-
ces were identical, presented di¡erent clinical manifestations.
By contrast, mother F, her daughter J and patient I presented
similar clinical characteristics (EI) although their viral sequen-
ces showed amino acid di¡erences in the vV region. Similarly,
nurses B and K both presented polyarthritis although their
viral vV regions were signi¢cantly di¡erent (namely, the N-
terminal vV sequence from nurse B was composed of basic
amino acids, while that from nurse K was composed of acidic
amino acids).
4. Discussion
Genetic variation among parvovirus B19 isolates has been
previously described [15,18,19]. During the present study, we
focused on major regions of VP1 and VP2 encoding sequences
based on the rationale that the NS1 encoding region is highly
conserved among parvovirus species [20]. In addition, NS1 in
parvovirus B19 does not elicit a detectable antibody response
in acutely infected individuals [21] and, thus, might not be
relevant in the context of an immunopathogenetic signi¢cance
of strain diversity [20]. Therefore, we have analyzed the nu-
cleotide and amino acid sequences of the VP1 unique region
(vV) as well as the junction region (VP1/VP2) that were am-
pli¢ed from the patients infected in a single outbreak. We
found that genetic heterogeneity among the eight B19 isolates
was restricted in the vV region, which was consistent with
previous reports [22,23]. We also found that there was no
signi¢cant correlation between viral genotypes and clinical
manifestations.
The nucleotide and amino acid sequences of the VP1 unique
region (vV) were less conserved than the VP1/VP2 junction
region among the six isolates studied. Since the N-terminus of
the vV unique region is reported to contain a neutralizing
immune response [10,11,14], amino acid variability in this re-
gion may alter the B19 immunogenicity. It was noted in this
study that the 3P sequence of the vV unique region was con-
served whereas the 5P sequence was relatively variable as re-
ported by Erdman and coworkers [19]. They indicated that
the conservation of the 3P sequence might be required for the
accurate splicing to generate mRNA encoding VP2 protein
[19,24].
The junction region (VP1/VP2) between the encoding se-
quences of the two structural proteins (VP1 and VP2) was
highly conserved and only a few nucleotide changes were
found. This junction region has been shown to contain neu-
tralizing epitopes [11]. We found that most nucleotide changes
in this region were silent mutations giving a much lower var-
iability at the protein level as found by Hemauer and co-
workers [15].
Recently, it was reported that viral protein NS1 induced
apoptosis in erythroid lineage cells and that it could also in-
duce IL-6 production [9,25]. Other reports demonstrated that
a putative nucleoside triphosphate-binding motif was indis-
pensable for the cytotoxic activity [26,27]. However, our visual
inspection of the reported NS1 sequences (several sequences
of NS1 have been published: B19-Au [18], Z68146, Z70528,
Z70560 and Z70599 [15] and accession number AF113323) did
not reveal any sequence heterogeneity in this region. Interest-
ingly, AF113323 was obtained from a patient with SLE-like
symptoms, whereas B19-Au was from a patient with aplastic
crisis. Although we cannot exclude a possibility that another
B19 protein, NS1, might be involved in clinical manifesta-
tions, no evidence has been reported to support that genetic
Fig. 3. Phylogenetic tree analyses of the parvovirus B19 isolates.
Dendrograms were generated from the nucleotide sequence corre-
sponding to the vV and the VP1/VP2 junction regions by the neigh-
bor-joining method [15]. The scale bar indicates the number of nu-
cleotide substitutions per site.
Table 2
Amino acid sequence heterogeneities among di¡erent HPV B19 iso-
lates from the vV unique region
B19-Aua Cases
aa position aa B C F-1 F-2 F-3 I J K
3 K ^ E ^ ^ ^ E E E
4 K ^ E ^ E ^ E E E
12 D N N N N N N N N
39 Q P ^ ^ ^ ^ ^ ^ ^
51 N ^ ^ ^ ^ ^ ^ H ^
103 P ^ ^ ^ ^ ^ ^ L ^
170 H ^ Y ^ ^ ^ ^ ^ Y
176 E ^ ^ ^ ^ ^ G ^ ^
229 T ^ ^ ^ P ^ ^ ^ ^
Total aa changes 2 4 1 3 1 4 5 4
aB19-Au, Shade-sequence (Shade et al., 1986).
Table 3
Amino acid sequence heterogeneities among di¡erent HPV B19 iso-
lates from the VP1/VP2 junction region
B19-Aua Cases
aa position aa B C F I J K
18 H ^ Y ^ ^ ^ Y
95 S P P P P P P
Total aa changes 1 2 1 1 1 2
aB19-Au, Shade-sequence (Shade et al., 1986).
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heterogeneity of NS1 could account for various clinical pic-
tures.
In a single community wide outbreak of parvovirus B19
infection such as reported here, one B19 genotype and its
quasi-species might predominate within a limited time span.
However, the clinical manifestations usually vary among in-
fected individuals. For example, nurse C exhibited positive
anti-nuclear antibody, polyarthritis and facial erythema (a
‘butter£y’ rash), resembling SLE, whereas nurse K, from
who the same parvovirus B19 sequence was identi¢ed, had
only transient polyarthritis. It is well known that B19 infec-
tion is usually mild and is predominantly associated with er-
ythema infectiosum while in adults, especially in women, it is
often associated with polyarthritis and this was con¢rmed by
the ¢ndings from this outbreak. Thus, these heterogeneities of
clinical manifestations are likely to be associated with the host
response against virus infection rather than virus isolate per
se.
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